SUBSCRIBE
SUBSCRIBE
News   Drug Development

Gentium S.p.A. to Amend Primary Goal for Cancer Drug Defibrotide

November 5, 2007 | 
1 min read
Nov 5 (Reuters) - Gentium S.p.A. (GENT.O: Quote, Profile, Research) said it plans to amend the protocol for its late-stage trial of cancer drug Defibrotide with the main goal for the study to change from survival at 100 days to complete response.
Clinical research Phase III
MORE ON THIS TOPIC
Focal seizure. Vector illustration of human brain and electroencephalograhy or EEG originating from temporal lobe.
Gene therapy
Capsida Reports Patient Death in Gene Therapy Trial
September 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Goal concept. Human hand in dotted pop art style pointing on the target for red paper plane. Vector illustration
Duchenne muscular dystrophy
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA
September 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company
Layoffs
Merck Abandons $1.3B R&D Center in London, Boots 125 Employees
September 11, 2025
 · 
1 min read
 · 
Tristan Manalac
Set your goals is shown using the collage with aim and the hand. Business targeting, aiming, focus concept and way to achieve a goal
Immunology and inflammation
Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful
September 10, 2025
 · 
2 min read
 · 
Tristan Manalac